KR20090061055A - 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법 - Google Patents

결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법 Download PDF

Info

Publication number
KR20090061055A
KR20090061055A KR1020097008048A KR20097008048A KR20090061055A KR 20090061055 A KR20090061055 A KR 20090061055A KR 1020097008048 A KR1020097008048 A KR 1020097008048A KR 20097008048 A KR20097008048 A KR 20097008048A KR 20090061055 A KR20090061055 A KR 20090061055A
Authority
KR
South Korea
Prior art keywords
imatinib
formula
desmethyl
base
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097008048A
Other languages
English (en)
Korean (ko)
Inventor
피터 린드세이 맥도널드
피에르루이지 로세토
알렉산드르 제고로프
안드레아 지오리토
다리오 텐토리오
아우구스토 카나베시
알레스 가벤다
Original Assignee
시코르, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시코르, 인크. filed Critical 시코르, 인크.
Publication of KR20090061055A publication Critical patent/KR20090061055A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020097008048A 2006-10-26 2007-10-26 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법 Ceased KR20090061055A (ko)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US85477406P 2006-10-26 2006-10-26
US60/854,774 2006-10-26
US86062406P 2006-11-22 2006-11-22
US60/860,624 2006-11-22
US87442006P 2006-12-11 2006-12-11
US60/874,420 2006-12-11
US93491107P 2007-06-14 2007-06-14
US60/934,911 2007-06-14
US95836707P 2007-07-05 2007-07-05
US60/958,367 2007-07-05
US96323807P 2007-08-02 2007-08-02
US60/963,238 2007-08-02
US96761707P 2007-09-05 2007-09-05
US60/967,617 2007-09-05
US99533207P 2007-09-25 2007-09-25
US60/995,332 2007-09-25
US99784907P 2007-10-05 2007-10-05
US60/997,849 2007-10-05
US97925607P 2007-10-11 2007-10-11
US60/979,256 2007-10-11

Publications (1)

Publication Number Publication Date
KR20090061055A true KR20090061055A (ko) 2009-06-15

Family

ID=39027276

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097008048A Ceased KR20090061055A (ko) 2006-10-26 2007-10-26 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법
KR1020097008519A Ceased KR20090061068A (ko) 2006-10-26 2007-10-26 이매티닙의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097008519A Ceased KR20090061068A (ko) 2006-10-26 2007-10-26 이매티닙의 제조 방법

Country Status (6)

Country Link
US (2) US20080103305A1 (https=)
EP (2) EP1966186A1 (https=)
JP (2) JP2009514988A (https=)
KR (2) KR20090061055A (https=)
MX (1) MX2008008447A (https=)
WO (2) WO2008057291A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2530077A1 (en) 2011-05-30 2012-12-05 Bcworld Pharm. Co. Ltd. Novel method for preparing imatinib base

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081556A1 (en) * 2007-09-25 2009-07-29 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
US20110306763A1 (en) 2009-12-10 2011-12-15 Shanghai Parling Pharmatech Co., Ltd. Process for the preparation of imatinib and salts thereof
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
EA024088B1 (ru) 2010-06-18 2016-08-31 КРКА, д.д., НОВО МЕСТО α-ФОРМА МЕЗИЛАТА ИМАТИНИБА, СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЁ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
WO2012015999A2 (en) * 2010-07-29 2012-02-02 Dr. Reddy's Laboratories Ltd. Process for the preparation of imatinib mesylate
CN101899035B (zh) * 2010-09-03 2012-09-05 天津市炜杰科技有限公司 一种高纯度伊马替尼的制备方法
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
EP2691385A4 (en) 2011-03-31 2014-08-13 Ind Swift Lab Ltd IMPROVED METHOD FOR THE PRODUCTION OF IMATINIB AND ITS MESYLATE SALT
WO2013008242A1 (en) * 2011-07-12 2013-01-17 Natco Pharma Limited A process for the preparation of highly pure 4-(4-methyl piperazinomethyl) benzoic acid dihydrochloride
CN102850297B (zh) * 2012-10-10 2014-07-23 山东金城医药化工股份有限公司 伊马酸的制备方法
KR101558960B1 (ko) 2013-07-18 2015-10-08 하나제약 주식회사 Ν-5-(4-[4-메틸-피페라지노-메틸]-벤조일아미도)-2-메틸페닐-4-[3-피리딜]-2-피리미딘-아민의 신규한 제조방법
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
CN103483314B (zh) * 2013-09-16 2015-02-18 南京优科生物医药研究有限公司 一种便捷的制备甲磺酸伊马替尼α晶型的方法
SE539450C2 (en) * 2016-02-29 2017-09-26 Imatinib for use in the treatment of stroke
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US20200360477A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Inhalable formulations for kinase inhibition
CN115850258B (zh) * 2022-12-27 2024-09-24 东北林业大学 一种马赛替尼的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623486A (en) * 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (https=) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US20030119060A1 (en) * 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
JP2003119184A (ja) * 2001-10-11 2003-04-23 Toray Ind Inc 置換ピペラジニルメチル芳香族酸誘導体の製造方法
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
AU2003232650A1 (en) * 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
AU2003237596A1 (en) * 2003-06-02 2005-01-21 Hetero Drugs Limited Novel polymorphs of imatinib mesylate
US7507821B2 (en) * 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
US20060223817A1 (en) * 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2530077A1 (en) 2011-05-30 2012-12-05 Bcworld Pharm. Co. Ltd. Novel method for preparing imatinib base

Also Published As

Publication number Publication date
WO2008057291B1 (en) 2008-08-21
JP2009514988A (ja) 2009-04-09
JP2009503120A (ja) 2009-01-29
US20080103305A1 (en) 2008-05-01
MX2008008447A (es) 2008-09-15
WO2008057291A2 (en) 2008-05-15
EP1966186A1 (en) 2008-09-10
US20080207904A1 (en) 2008-08-28
WO2008057291A3 (en) 2008-07-03
KR20090061068A (ko) 2009-06-15
WO2008051597A1 (en) 2008-05-02
EP2076507A2 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
KR20090061055A (ko) 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법
KR102715956B1 (ko) 리보시클립 염 및 이의 고상 형태
US20210017188A1 (en) Solid state forms of relugolix
US20210387952A1 (en) Solid state forms of daprodustat and process for preparation thereof
US20240391916A1 (en) Solid state forms of ensifentrine and process for preparation thereof
US20240368348A1 (en) Solid state forms of sugammadex sodium
US20220372019A1 (en) Salts and solid state forms of plinabulin
US12441738B2 (en) Solid state forms of Relugolix
US20240199578A1 (en) Solid state forms of zavegepant and process for preparation thereof
US12492213B2 (en) Solid state forms of sep-363856 and process for preparation thereof
EP1988089A1 (en) Imatinib base, and imatinib mesylate and processes for preparation thereof
EP1507531B1 (en) Stable pharmaceutical compositions of desloratadine
US20250171448A1 (en) Solid state forms of gusacitinib
US12404267B2 (en) Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide and of its mesylate salt
WO2022020279A1 (en) Solid state forms of selpercatinib and process for preparation thereof
US20250276959A1 (en) Solid state forms of zavegepant hydrochloride and process for preparation thereof
WO2024095127A1 (en) Solid state forms of tivozanib and process for preparation thereof
US20240254122A1 (en) Process for preparation of sotorasib and solid state form thereof
CA3248508A1 (en) SOLID STATE FORMS OF MAVACAMTEN AND THEIR PREPARATION METHOD
US20220153744A1 (en) Solid state forms of acalabrutinib
US20240010632A1 (en) Solid state forms of erdafitinib salts and processes for preparation of erdafitinib
US20240279167A1 (en) Crystalline polymorphs of rigosertib sodium
US20240279195A1 (en) Solid state forms of abexinostat and process for preparation thereof
US20240246914A1 (en) Solid state form of centanafadine hcl and process for preparation thereof
US20230373998A1 (en) Solid state forms of lorecivivint

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000